BCRX
BioCryst Pharmaceuticals Inc
NASDAQ: BCRX · HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC
$8.99
+1.47% today
Updated 2026-04-29
Market cap
$2.28B
P/E ratio
7.43
P/S ratio
2.61x
EPS (TTM)
$1.21
Dividend yield
—
52W range
$6 – $11
Volume
5.5M
BioCryst Pharmaceuticals Inc (BCRX) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
6 of 8
Last 8 quarters
Avg EPS surprise
+150.0%
Last 4 quarters
Revenue YoY growth
+209.1%
Most recent quarter
EPS YoY growth
+962.5%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-1.8%
Last 3 reports
Positive reaction rate
33%
1 of 3 quarters
Largest single-day move
-7.7%
2025-11-03
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-25 | $1.12 | +3159.3% | $7.61 | $7.90 | +3.8% |
| 2025-11-03 | $0.16 | +220.0% | $7.32 | $6.76 | -7.7% |
| 2025-08-05 | $0.02 | +100.0% | $8.73 | $8.60 | -1.5% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $0.03 | $1.12 | +3159.3% | $406.56M | +209.1% |
| 2025-09-30 | $0.05 | $0.16 | +220.0% | $159.40M | +36.1% |
| 2025-06-30 | $0.01 | $0.02 | +100.0% | $163.35M | +49.4% |
| 2025-03-31 | $-0.21 | $0.00 | +100.0% | $145.53M | +56.9% |
| 2024-12-31 | $-0.06 | $-0.13 | -115.2% | $131.53M | +40.8% |
| 2024-09-30 | $-0.06 | $-0.07 | -16.7% | $117.08M | +35.0% |
| 2024-06-30 | $-0.17 | $-0.06 | +64.7% | $109.33M | +32.5% |
| 2024-03-31 | $-0.21 | $-0.17 | +19.0% | $92.76M | +34.9% |
| 2023-12-31 | $-0.24 | $-0.28 | -16.7% | $93.40M | — |
| 2023-09-30 | $-0.23 | $-0.19 | +17.4% | $86.74M | — |
| 2023-06-30 | $-0.23 | $-0.24 | -4.3% | $82.49M | — |
| 2023-03-31 | $-0.30 | $-0.28 | +6.7% | $68.78M | — |
Frequently asked questions
Has BioCryst Pharmaceuticals Inc beaten earnings estimates?
BioCryst Pharmaceuticals Inc has beaten Wall Street EPS estimates in 6 of its last 8 quarterly reports, with an average EPS surprise of +150.0% over the last 2 quarters.
How does BCRX stock react to earnings?
BCRX stock has moved an average of -1.8% in the trading day following earnings over its last 3 reports, with positive reactions in 33% of those quarters.
What is BioCryst Pharmaceuticals Inc's revenue growth rate?
BioCryst Pharmaceuticals Inc reported year-over-year revenue growth of +209.1% in its most recent quarter, with EPS growing +962.5% year-over-year.